AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27771617 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control program
Number of subjects: 95
Study 25778685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU/day)
Number of subjects: 36
Study 25778685 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 μg/day)
Number of subjects: 36
Study 23435693 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope
Number of subjects: 134
Study 23435693 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview PCD video laryngoscope
Number of subjects: 134
Study 23435693 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (Macintosh blade)
Number of subjects: 134
Study 21161329 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10-20%)
Number of subjects: 37
Study 21161329 — intervention group
Group type: COMPARATOR
Intervention: Reactive warfarin dose adjustment
Number of subjects: 37
Study 19524987 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block and intraprostatic local anesthesia with 5 ml 2% lidocaine
Number of subjects: 300
Study 19524987 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block with 0.9% NaCl by intraprostatic injection
Number of subjects: 300
Study 19524987 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 300
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG abnormalities in fetuses with metabolic acidaemia
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment abnormalities in fetuses with metabolic acidaemia
Number of subjects: 142
Study 15663579 — intervention group
Group type: COMPARATOR
Intervention: CTG abnormalities in controls
Number of subjects: 142
Study 15663579 — intervention group
Group type: COMPARATOR
Intervention: ST segment abnormalities in controls
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication for intervention based on CTG in cases with acidaemia
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication for intervention based on CTG + ST in cases with acidaemia
Number of subjects: 142
Study 15663579 — intervention group
Group type: COMPARATOR
Intervention: Indication for intervention based on CTG in controls
Number of subjects: 142
Study 15663579 — intervention group
Group type: COMPARATOR
Intervention: Indication for intervention based on CTG + ST in controls
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for ST abnormalities
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for CTG abnormalities
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for indication to intervene based on CTG + ST
Number of subjects: 142
Study 15663579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for indication to intervene based on CTG alone
Number of subjects: 142
Study 12578443 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with tympanostomy
Number of subjects: 306
Study 12578443 — intervention group
Group type: COMPARATOR
Intervention: Tympanostomy only (Control)
Number of subjects: 306
Study 10522590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 80
Study 10522590 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (3 mg)
Number of subjects: 80
Study 8886862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 300 micrograms
Number of subjects: 0
Study 8886862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 100 micrograms
Number of subjects: 0
Study 8886862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 300-1000 micrograms
Number of subjects: 0
Study 8886862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 1000 micrograms
Number of subjects: 0
Study 8886862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 300 micrograms or 1000 micrograms
Number of subjects: 0
Study 1792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (N)
Number of subjects: 419
Study 1792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PP)
Number of subjects: 419
Study 1792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (PS)
Number of subjects: 419
Study 1792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (D)
Number of subjects: 419
Study 1792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (2-3 drugs)
Number of subjects: 419
Study 1792613 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 419
Study 6349944 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen agent
Number of subjects: 53
Study 6349944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 53
Study 30712444 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session cognitive behavior treatment (CBT)
Number of subjects: 56
Study 30712444 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 30396331 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised questionnaires and tests for clinical, neuropsychological, behavioural and health-economic assessments.
Number of subjects: 0
Study 30396331 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study exploring health care needs and experiences of patients and carers.
Number of subjects: 0
Study 30396331 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional sub-study evaluating impact of specialist recommendations.
Number of subjects: 0
Study 27197690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1 g intravenous on days 1 and 15, and after 26 weeks if needed)
Number of subjects: 295
Study 27197690 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitor (adalimumab 40 mg subcutaneously every other week or etanercept 50 mg per week subcutaneously)
Number of subjects: 295
Study 27197690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 295
Study 27197690 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitor
Number of subjects: 295
Study 24317854 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification (Irvine method)
Number of subjects: 568
Study 24317854 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification (Vitrolife method)
Number of subjects: 568
Study 24317854 — intervention group
Group type: COMPARATOR
Intervention: Slow freezing
Number of subjects: 568
Study 22045836 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus MTX
Number of subjects: 799
Study 22045836 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 799
Study 22045836 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 799
Study 19382479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianhuang Decoction (LHD)
Number of subjects: 60
Study 19382479 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 17369792 — intervention group
Group type: EXPERIMENTAL
Intervention: Once per week leg press exercise (n=10)
Number of subjects: 21
Study 17369792 — intervention group
Group type: COMPARATOR
Intervention: Twice per week leg press exercise (n=11)
Number of subjects: 21
Study 16311972 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfused arteries
Number of subjects: 32
Study 16311972 — intervention group
Group type: COMPARATOR
Intervention: Clipped arteries
Number of subjects: 32
Study 12042579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postnatal dexamethasone (0.5 mg/kg/d for the first 3 days, 0.25 mg/kg/d for the next 3 days, and 0.125 mg/kg/d on the seventh day)
Number of subjects: 50
Study 12042579 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated neonates)
Number of subjects: 50
Study 9856295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 60
Study 9856295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 8522734 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral sympathectomy
Number of subjects: 7
Study 8522734 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7 extremities)
Number of subjects: 7
Study 2087938 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose diet (30 g/day)
Number of subjects: 12
Study 2087938 — intervention group
Group type: COMPARATOR
Intervention: control diet (high-carbohydrate high-fiber diet)
Number of subjects: 12
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg orally
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg orally
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.2 mg/kg intravenously
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 0.2 mg/kg intravenously
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg orally
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 0.2 mg/kg intravenously
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 200 mg orally
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 1 mg/kg intravenously
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 0.05 mg/kg intravenously
Number of subjects: 2
Study 23136 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 2
Study 31410966 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom-catheter uterine balloon tamponade (UBT) introduced after training and provision of kits.
Number of subjects: 28183
Study 31410966 — intervention group
Group type: COMPARATOR
Intervention: Control period (before UBT introduction).
Number of subjects: 28183
Study 29267567 — intervention group
Group type: COMPARATOR
Intervention: Traditional upper blepharoplasty with a single running suture skin closure
Number of subjects: 50
Study 29267567 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper blepharoplasty with brassiere sutures (orbicularis oculi muscle fixation to the periosteum)
Number of subjects: 50
Study 26358523 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 26358523 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with chemotherapy
Number of subjects: 0
Study 23596888 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower peony ointment single dosage scheme (2.16 g, 4 people; 4.32 g, 6 people; 6.48 g, 6 people; 8.62 g, 6 people; 11.46 g, 6 people; 15.24 g, 6 people) for 24 hours, once every day.
Number of subjects: 46
Study 23596888 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower peony ointment multi-dosage scheme (8.62 g, 6 people; 11.46 g, 6 people) once every day for 7 days.
Number of subjects: 46
Study 21539525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Drug Burden Index (DBI <1)
Number of subjects: 602
Study 21539525 — intervention group
Group type: EXPERIMENTAL
Intervention: High Drug Burden Index (DBI ≥1)
Number of subjects: 602
Study 21539525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Drug Burden Index (DBI <1) after adjustment
Number of subjects: 602
Study 21539525 — intervention group
Group type: EXPERIMENTAL
Intervention: High Drug Burden Index (DBI ≥1) after adjustment
Number of subjects: 602
Study 19536689 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgun with female perpetrator
Number of subjects: 0
Study 19536689 — intervention group
Group type: EXPERIMENTAL
Intervention: Folding knife with female perpetrator
Number of subjects: 0
Study 19536689 — intervention group
Group type: COMPARATOR
Intervention: Knitting needle with female perpetrator
Number of subjects: 0
Study 19536689 — intervention group
Group type: EXPERIMENTAL
Intervention: Folding knife with male perpetrator
Number of subjects: 0
Study 19536689 — intervention group
Group type: COMPARATOR
Intervention: Dangerous perception of perpetrators (both genders)
Number of subjects: 0
Study 16829772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing interventions for smoking cessation
Number of subjects: 0
Study 16829772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation interventions
Number of subjects: 0
Study 12162857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxepin
Number of subjects: 12
Study 12162857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxepin
Number of subjects: 12
Study 10550137 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF priming
Number of subjects: 20
Study 7800338 — intervention group
Group type: EXPERIMENTAL
Intervention: IFO 2.5 g/m2 days 1‐2 + EPI 70 mg/m2 day 1 + cisplatin (DDP) 70 mg/m2 day 1 (arm IEP)
Number of subjects: 203
Study 7800338 — intervention group
Group type: COMPARATOR
Intervention: IFO 2.5 g/m2 days 1‐2 + EPI 70 mg/m2 day 1 (arm IE)
Number of subjects: 203
Study 2349954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation, 100 mg/kg/day for 2 months
Number of subjects: 12
Study 2349954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral L-carnitine supplementation)
Number of subjects: 12
Study 2349954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 12
Study 159841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 11‐1430 (0.1% vanishing cream)
Number of subjects: 29
Study 159841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vanishing cream alone)
Number of subjects: 29
Study 159841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 11‐1430
Number of subjects: 29
Study 159841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29603005 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D/HD monitor
Number of subjects: 11
Study 29603005 — intervention group
Group type: COMPARATOR
Intervention: 2D/4K monitor
Number of subjects: 11
Study 29603005 — intervention group
Group type: COMPARATOR
Intervention: 2D/HD monitor
Number of subjects: 11
Study 25715022 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 50
Study 25715022 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 50
Study 25715022 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 50
Study 25715022 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube
Number of subjects: 50
Study 25715022 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tubes
Number of subjects: 50
Study 25594845 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-improving cream (5% urea)
Number of subjects: 0
Study 25594845 — intervention group
Group type: COMPARATOR
Intervention: Reference cream
Number of subjects: 0
Study 24076337 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% albumin (2 g/kg; maximum dose 750 mL)
Number of subjects: 841
Study 24076337 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (equivalent volume)
Number of subjects: 841
Study 20677054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs
Number of subjects: 4685
Study 20677054 — intervention group
Group type: COMPARATOR
Intervention: Text and Tables
Number of subjects: 4685
Study 18534594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg dose)
Number of subjects: 122
Study 17038253 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine + TPN (0.27 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 40
Study 17038253 — intervention group
Group type: COMPARATOR
Intervention: Routine TPN
Number of subjects: 40
Study 17038253 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine + TPN
Number of subjects: 40
Study 12201967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Strategy (CDS)
Number of subjects: 362
Study 12201967 — intervention group
Group type: COMPARATOR
Intervention: Surgical strategy (Euro-S)
Number of subjects: 362
Study 9708223 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 23
Study 8543875 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-portal endoscopic release
Number of subjects: 96
Study 8543875 — intervention group
Group type: COMPARATOR
Intervention: Conventional palmar open release
Number of subjects: 96
Study 2223274 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling program
Number of subjects: 2489
Study 2223274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2489
Study 153716 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback from abdominal muscles
Number of subjects: 12
Study 153716 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback from frontalis muscles
Number of subjects: 12
Study 153716 — intervention group
Group type: COMPARATOR
Intervention: No EMG treatment (control group)
Number of subjects: 12
Study 31416011 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07 (5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg)
Number of subjects: 71
Study 31416011 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07 (5 mg to 100 mg)
Number of subjects: 71
Study 31416011 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07
Number of subjects: 71
Study 28901534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (0.5 mg/kg/d)
Number of subjects: 40
Study 28901534 — intervention group
Group type: COMPARATOR
Intervention: Topical isotretinoin (0.05% gel, once daily at night)
Number of subjects: 40
Study 26277764 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 0
Study 26277764 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 0
Study 26277764 — intervention group
Group type: COMPARATOR
Intervention: NYHA functional class II
Number of subjects: 0
Study 24867353 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 hours (16 weeks) of cognitive training
Number of subjects: 30
Study 24867353 — intervention group
Group type: COMPARATOR
Intervention: Computer games control condition
Number of subjects: 30
Study 22546262 — intervention group
Group type: EXPERIMENTAL
Intervention: Serving fruits and vegetables in advance of other menu items (0.40 servings/meal)
Number of subjects: 53
Study 22546262 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider portioned meals
Number of subjects: 53
Study 22546262 — intervention group
Group type: COMPARATOR
Intervention: Traditional family style meal service (control)
Number of subjects: 53
Study 18574608 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytherapy with two atypical antipsychotics
Number of subjects: 364
Study 18574608 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with atypical antipsychotics
Number of subjects: 364
Study 17301646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily
Number of subjects: 1303
Study 17301646 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 1303
Study 15064101 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 20
Study 15064101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 20
Study 15064101 — intervention group
Group type: COMPARATOR
Intervention: Animal protein
Number of subjects: 20
Study 11966543 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (acid decreasing therapy with H2-receptor antagonist or PPI)
Number of subjects: 445
Study 11966543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (one antibiotic plus acid-decreasing therapy)
Number of subjects: 445
Study 11966543 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (PPI plus amoxicillin and clarithromycin)
Number of subjects: 445
Study 9709461 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate AZT monotherapy
Number of subjects: 0
Study 9709461 — intervention group
Group type: COMPARATOR
Intervention: Deferred AZT monotherapy
Number of subjects: 0
Study 8620950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose salbutamol metered-dose inhaler (50 micrograms.puff-1)
Number of subjects: 20
Study 8620950 — intervention group
Group type: COMPARATOR
Intervention: Standard dose salbutamol metered-dose inhaler (100 micrograms.puff-1)
Number of subjects: 20
Study 28964720 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (group-based, behavioral weight-loss program led by community health workers)
Number of subjects: 301
Study 28964720 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care condition (dietary counseling and written materials)
Number of subjects: 301
Study 25249408 — intervention group
Group type: EXPERIMENTAL
Intervention: Social threat
Number of subjects: 0
Study 25249408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response to the stressor
Number of subjects: 0
Study 25394818 — intervention group
Group type: EXPERIMENTAL
Intervention: PC6 acupoint stimulation using acupressure wristbands for 36 hours
Number of subjects: 712
Study 25394818 — intervention group
Group type: COMPARATOR
Intervention: Placebo wristbands
Number of subjects: 712
Study 23723250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 9033
Study 23723250 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 9033
Study 20493771 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 889
Study 20493771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study 19348656 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 22
Study 19348656 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 22
Study 19348656 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with inflammatory skin diseases)
Number of subjects: 22
Study 17679954 — intervention group
Group type: EXPERIMENTAL
Intervention: Perftoran infusions with basic therapy
Number of subjects: 85
Study 17679954 — intervention group
Group type: COMPARATOR
Intervention: Basic conservative therapy (control group)
Number of subjects: 85
Study 15067650 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Stabilized (PS) TKA
Number of subjects: 20